Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.
Identifieur interne : 001E48 ( PubMed/Corpus ); précédent : 001E47; suivant : 001E49Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.
Auteurs : Els Keyaerts ; Leen Vijgen ; Christophe Pannecouque ; Els Van Damme ; Willy Peumans ; Herman Egberink ; Jan Balzarini ; Marc Van RanstSource :
- Antiviral research [ 0166-3542 ] ; 2007.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (metabolism), Antiviral Agents (pharmacology), Cats, Cell Line, Coronavirus, Feline (drug effects), Coronavirus, Feline (physiology), Humans, Liliaceae, Plant Lectins (metabolism), Plant Lectins (pharmacology), SARS Virus (drug effects), SARS Virus (physiology), Virus Internalization (drug effects), Virus Replication (drug effects).
- MESH :
- chemical , metabolism : Antiviral Agents, Plant Lectins.
- chemical , pharmacology : Antiviral Agents, Plant Lectins.
- drug effects : Coronavirus, Feline, SARS Virus, Virus Internalization, Virus Replication.
- physiology : Coronavirus, Feline, SARS Virus.
- Animals, Cats, Cell Line, Humans, Liliaceae.
Abstract
We describe the antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome coronavirus (SARS-CoV) and the feline infectious peritonitis virus (FIPV) in vitro. The SARS-CoV emerged in 2002 as an important cause of severe lower respiratory tract infection in humans, and FIPV infection causes a chronic and often fatal peritonitis in cats. A unique collection of 33 plant lectins with different specificities were evaluated. The plant lectins possessed marked antiviral properties against both coronaviruses with EC(50) values in the lower microgram/ml range (middle nanomolar range), being non-toxic (CC(50)) at 50-100 microg/ml. The strongest anti-coronavirus activity was found predominantly among the mannose-binding lectins. In addition, a number of galactose-, N-acetylgalactosamine-, glucose-, and N-acetylglucosamine-specific plant agglutinines exhibited anti-coronaviral activity. A significant correlation (with an r-value of 0.70) between the EC(50) values of the 10 mannose-specific plant lectins effective against the two coronaviruses was found. In contrast, little correlation was seen between the activity of other types of lectins. Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV. The first target is located early in the replication cycle, most probably viral attachment, and the second target is located at the end of the infectious virus cycle.
DOI: 10.1016/j.antiviral.2007.03.003
PubMed: 17428553
Links to Exploration step
pubmed:17428553Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.</title>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation><nlm:affiliation>Laboratory of Clinical & Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
</author>
<author><name sortKey="Pannecouque, Christophe" sort="Pannecouque, Christophe" uniqKey="Pannecouque C" first="Christophe" last="Pannecouque">Christophe Pannecouque</name>
</author>
<author><name sortKey="Van Damme, Els" sort="Van Damme, Els" uniqKey="Van Damme E" first="Els" last="Van Damme">Els Van Damme</name>
</author>
<author><name sortKey="Peumans, Willy" sort="Peumans, Willy" uniqKey="Peumans W" first="Willy" last="Peumans">Willy Peumans</name>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
</author>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17428553</idno>
<idno type="pmid">17428553</idno>
<idno type="doi">10.1016/j.antiviral.2007.03.003</idno>
<idno type="wicri:Area/PubMed/Corpus">001E48</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E48</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.</title>
<author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name>
<affiliation><nlm:affiliation>Laboratory of Clinical & Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name>
</author>
<author><name sortKey="Pannecouque, Christophe" sort="Pannecouque, Christophe" uniqKey="Pannecouque C" first="Christophe" last="Pannecouque">Christophe Pannecouque</name>
</author>
<author><name sortKey="Van Damme, Els" sort="Van Damme, Els" uniqKey="Van Damme E" first="Els" last="Van Damme">Els Van Damme</name>
</author>
<author><name sortKey="Peumans, Willy" sort="Peumans, Willy" uniqKey="Peumans W" first="Willy" last="Peumans">Willy Peumans</name>
</author>
<author><name sortKey="Egberink, Herman" sort="Egberink, Herman" uniqKey="Egberink H" first="Herman" last="Egberink">Herman Egberink</name>
</author>
<author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name>
</author>
<author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (metabolism)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cats</term>
<term>Cell Line</term>
<term>Coronavirus, Feline (drug effects)</term>
<term>Coronavirus, Feline (physiology)</term>
<term>Humans</term>
<term>Liliaceae</term>
<term>Plant Lectins (metabolism)</term>
<term>Plant Lectins (pharmacology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Virus Internalization (drug effects)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term>
<term>Plant Lectins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Plant Lectins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus, Feline</term>
<term>SARS Virus</term>
<term>Virus Internalization</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus, Feline</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cats</term>
<term>Cell Line</term>
<term>Humans</term>
<term>Liliaceae</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We describe the antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome coronavirus (SARS-CoV) and the feline infectious peritonitis virus (FIPV) in vitro. The SARS-CoV emerged in 2002 as an important cause of severe lower respiratory tract infection in humans, and FIPV infection causes a chronic and often fatal peritonitis in cats. A unique collection of 33 plant lectins with different specificities were evaluated. The plant lectins possessed marked antiviral properties against both coronaviruses with EC(50) values in the lower microgram/ml range (middle nanomolar range), being non-toxic (CC(50)) at 50-100 microg/ml. The strongest anti-coronavirus activity was found predominantly among the mannose-binding lectins. In addition, a number of galactose-, N-acetylgalactosamine-, glucose-, and N-acetylglucosamine-specific plant agglutinines exhibited anti-coronaviral activity. A significant correlation (with an r-value of 0.70) between the EC(50) values of the 10 mannose-specific plant lectins effective against the two coronaviruses was found. In contrast, little correlation was seen between the activity of other types of lectins. Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV. The first target is located early in the replication cycle, most probably viral attachment, and the second target is located at the end of the infectious virus cycle.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17428553</PMID>
<DateCompleted><Year>2007</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-3542</ISSN>
<JournalIssue CitedMedium="Print"><Volume>75</Volume>
<Issue>3</Issue>
<PubDate><Year>2007</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.</ArticleTitle>
<Pagination><MedlinePgn>179-87</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We describe the antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome coronavirus (SARS-CoV) and the feline infectious peritonitis virus (FIPV) in vitro. The SARS-CoV emerged in 2002 as an important cause of severe lower respiratory tract infection in humans, and FIPV infection causes a chronic and often fatal peritonitis in cats. A unique collection of 33 plant lectins with different specificities were evaluated. The plant lectins possessed marked antiviral properties against both coronaviruses with EC(50) values in the lower microgram/ml range (middle nanomolar range), being non-toxic (CC(50)) at 50-100 microg/ml. The strongest anti-coronavirus activity was found predominantly among the mannose-binding lectins. In addition, a number of galactose-, N-acetylgalactosamine-, glucose-, and N-acetylglucosamine-specific plant agglutinines exhibited anti-coronaviral activity. A significant correlation (with an r-value of 0.70) between the EC(50) values of the 10 mannose-specific plant lectins effective against the two coronaviruses was found. In contrast, little correlation was seen between the activity of other types of lectins. Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV. The first target is located early in the replication cycle, most probably viral attachment, and the second target is located at the end of the infectious virus cycle.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keyaerts</LastName>
<ForeName>Els</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Laboratory of Clinical & Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vijgen</LastName>
<ForeName>Leen</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pannecouque</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Van Damme</LastName>
<ForeName>Els</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Peumans</LastName>
<ForeName>Willy</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Egberink</LastName>
<ForeName>Herman</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Balzarini</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Van Ranst</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2007</Year>
<Month>03</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037121">Plant Lectins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016765" MajorTopicYN="N">Coronavirus, Feline</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019668" MajorTopicYN="N">Liliaceae</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037121" MajorTopicYN="N">Plant Lectins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year>
<Month>12</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2007</Year>
<Month>03</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2007</Year>
<Month>03</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>4</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>11</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>4</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17428553</ArticleId>
<ArticleId IdType="pii">S0166-3542(07)00238-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2007.03.003</ArticleId>
<ArticleId IdType="pmc">PMC7114093</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Int J Infect Dis. 2006 Jan;10(1):32-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16023880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>AIDS. 1989 Oct;3(10):635-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2574581</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):503-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15655772</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2005 Dec 9;280(49):41005-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16183648</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 1992 Jun;18(2):191-207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1329650</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 1980;5(3):221-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6262450</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Acquir Immune Defic Syndr (1988). 1988;1(5):453-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2906092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1991 Mar;35(3):410-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1645507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Apr 15;329(3):1147-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15752773</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Med Microbiol Immunol. 1990;179(5):225-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2082156</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Cell Proteomics. 2003 May;2(5):346-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12775768</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>BMC Infect Dis. 2005 Feb 01;5:6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15686594</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2006 Mar 1;42(5):634-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16447108</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 1989 Oct;5(5):495-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2686727</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Plant J. 2003 Jan;33(2):293-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12535343</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2004 Oct;48(10):3858-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15388446</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2004 Aug 19;351(8):743-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15317885</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Virol. 2006 Jan;35(1):99-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16257260</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FASEB J. 2002 Jun;16(8):905-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12039875</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2005 Mar;75(3):455-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15648064</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Virol. 2003 Nov;148(11):2207-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14579179</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Vet Res. 1981 Mar;42(3):368-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6267960</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Plant Physiol. 2002 Oct;130(2):757-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12376642</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Jan;79(2):884-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15613317</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12557-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507643</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:17428553 |texte= Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17428553" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |